IPCA Laboratories Ltd
Ticker: IPCALAB
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
1297.30
Market Cap
32913.05
Debt/Equity
0.1625
ROE %
9.155
PB
3.9237
Promoter %
44.724
Pledge %
0.000
1Y Rev Growth %
14.366
5Y Rev Growth %
14.025
NP Margin %
8.167
NP Margin 5Y Avg %
11.657
Trading Reference
1M Return %
-0.978
6M Return %
-5.168
1Y Return %
-23.834
% Away 52W High
35.350
% Away 52W Low
11.051
Daily Volume
96247
Investment Verdict
Hold
Score 64/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 20/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
IPCA Laboratories Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the recent resistance level, it could see significant upside. However, if it falls below the support, there could be a notable downside risk.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
G
Gland Pharma Ltd
Gland Pharma shows potential for growth but faces challenges in profitability and market competition.
View details
M
Motherson Sumi Wiring India Ltd
Motherson Sumi Wiring India Ltd shows potential for growth in a future-ready sector, but faces challenges in profitability consistency and valuation metrics.
View details
G
Go Digit General Insurance Ltd
Go Digit General Insurance Ltd shows potential for growth in a digital-first insurance market, but faces challenges in profitability and execution risks.
View details
H
Honeywell Automation India Ltd
Honeywell Automation India Ltd shows a decent investment potential with strong growth prospects, but valuation concerns and execution risks should be monitored.
View details
C
Central Bank of India Ltd
The Central Bank of India Ltd presents a risky investment opportunity due to inconsistent growth, profitability concerns, and high valuation metrics.
View details
A
Aster DM Healthcare Ltd
Aster DM Healthcare shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
View details
G
Gillette India Ltd
Gillette India Ltd shows decent fundamentals with stable growth prospects, but faces challenges in profitability and valuation metrics.
View details
C
Central Depository Services (India) Ltd
The company shows decent fundamentals with growth potential, but faces challenges in profitability and valuation metrics.
View details
A
Ajanta Pharma Ltd
Ajanta Pharma shows potential for growth but faces challenges in profitability and valuation.
View details
E
Embassy Office Parks REIT
Embassy Office Parks REIT shows potential for growth but faces challenges in profitability and valuation. Caution is advised.
View details
N
New India Assurance Company Ltd
The stock shows moderate potential but lacks strong growth drivers and faces some risks.
View details
E
Elitecon International Ltd
Elitecon International Ltd shows potential but faces challenges in growth consistency and market sentiment.
View details
L
LIC Housing Finance Ltd
LIC Housing Finance Ltd shows potential for growth but faces challenges in profitability and valuation. Caution is advised.
View details
K
Krishna Institute of Medical Sciences Ltd
The stock shows decent potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
A
Apollo Tyres Ltd
Apollo Tyres Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
I
Indraprastha Gas Ltd
Indraprastha Gas Ltd shows decent fundamentals with growth potential, but investors should be cautious of execution risks and valuation levels.
View details
Business Overview
IPCA Laboratories Ltd is a leading Indian pharmaceutical company engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). With a strong commitment to quality and innovation, IPCA serves both domestic and international markets, making it a trusted partner for healthcare providers and patients alike. The company plays a vital role in ensuring access to affordable medicines, contributing to the overall health landscape in India.
- Established leader in pharmaceuticals
- Wide range of quality products
- Strong domestic and international presence
- Focus on research and innovation
- Commitment to affordable healthcare
- Robust manufacturing capabilities
Investment Thesis
IPCA Laboratories Ltd stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. These factors position the company for sustained growth and profitability, making it a compelling investment opportunity for retail investors.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services aligns with market trends.
- Attractive valuation metrics compared to industry peers indicate a buying opportunity.
- Consistent financial performance showcases resilience and operational efficiency.
- Strategic focus on R&D ensures innovation and competitive advantage.
Opportunity vs Risk
Opportunities
- Strong product pipeline
- Growing demand for pharmaceuticals
- Expansion into international markets
- R&D investment increasing
- Strategic partnerships with healthcare firms
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in generics
- Supply chain disruptions
- Currency fluctuation risks
- Rising raw material costs
Peer Perspective
IPCA Laboratories Ltd is currently trading at a discount compared to peers like Sun Pharma and Dr. Reddy's, primarily due to margin pressures. A stabilization in margins could trigger a rerating, aligning its valuation more closely with competitors.
Future Outlook
IPCA Laboratories Ltd is well-positioned for future growth, driven by strong product pipelines and expanding market presence, provided they maintain effective execution and cost control to navigate potential market challenges.
AI FAQs for Retail Users
- Q: What does IPCA Laboratories do?A: IPCA Laboratories is a pharmaceutical company that manufactures and sells a variety of medicines.
- Q: Is IPCA Laboratories a good investment?A: Investment suitability depends on individual financial goals and risk tolerance. Research before investing.
- Q: What are the key products of IPCA Laboratories?A: IPCA produces generic and branded formulations, including antibiotics, cardiovascular, and anti-diabetic medications.
- Q: How has IPCA Laboratories performed recently?A: Recent performance can be checked through financial reports and stock market analysis.
- Q: Where can I find more information about IPCA Laboratories?A: You can visit their official website or check financial news platforms for updates.
📊 Stock Investment Checklist (100 Points)
IPCA Laboratories Ltd • Updated: 2025-09-17 02:47:44
-
10BusinessHighPharmaceutical sector is essential and growing, but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth over the past few years, but profit margins have fluctuated.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow has been inconsistent.
-
8ValuationHighP/E ratio is higher than industry average, indicating potential overvaluation.
-
7BalanceHighModerate debt levels, but liquidity ratios are satisfactory.
-
6GovernanceGoodPromoter holding is strong, but some concerns over pledging.
-
5DriversGoodGrowth drivers exist, but execution risks are notable.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
IPCA Laboratories Ltd shows potential for growth, but investors should be cautious due to profitability inconsistencies and valuation concerns.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 80/100
- Governance: 65/100
- Market Confidence: 72/100